Press release, Helsinki, 5 June 2017, there is a 14.00
Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or the “company“), a medical device company that developed and markets a ground-breaking system to navigate a non-invasive brain stimulation for therapeutic and diagnostic applications, announces that the Nexstim Plc’s board of directors has decided to Tomas Holmberg to replace Martin Jamieson of the remuneration committee. Risto Ilmoniemi, and Juliet Thompson were elected new members of the nominating committee. After the above mentioned changes have Nexstim Plc’s board committees with the following composition:
Chairman of the board, the audit committee is Juliet Thompson and the members are Rohan J. Hoare and Tomas Holmberg.
Chairman of the board, the remuneration committee is Ken Charhut, and the members are Rohan J. Hoare and Tomas Holmberg.
The chairman of the committee is Sami Tuhkanen and the members are Risto Ilmoniemi and Juliet Thompson.
Martin Jamieson, chairman of the board and ceo
Additional information is available on the website
or per telephone:
Nexstim +44 771 516 39 42
Martin Jamieson, chairman of the board and ceo email@example.com
UB Securities Oy (Certified Adviser) +358 (0)9 2538 02 46
Citigate Dewe Rogerson +44 (0)207 2821066
Katja Stout firstname.lastname@example.org
About Nexstim Plc
Nexstim is a medical device company that developed and markets a ground-breaking system to navigate a non-invasive brain stimulation for therapeutic applications (NBT®system) and diagnostic applications (NBS-system). Nexstims NBS system is the first and only FDA-approved and CE-marked system to navigate transcranial magnetic stimulation (navigated Transcranial Magnetic Stimulation, nTMS) for mapping of the areas of motor skills and speech in the brain before a surgical procedure.
On the same technology platform the company has developed a system to navigate hjärnterapi (Navigated Brain Therapy, NBT®), which has received CE marking for the treatment of stroke, severe depression and chronic neuropathic pain. The NBT®system is currently undergoing additional Phase III trials (E-FIT) with 60 patients. Nexstim expects the trial ends the second quarter of 2018 and that the company then can request for authorization from the FDA. With the approval from the FDA would Nexstim able to begin marketing and selling the NBT®system for the treatment of stroke in the united states.
Nexstims shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. More information is available at www.nexstim.com.
The composition of the Nexstim Plc’s board committees